alexa Cardiogenic shock | United States| PDF | PPT| Case Reports | Symptoms | Treatment

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Cardiogenic Shock

  • Cardiogenic shock

    Patho physiology: Cardiogenic shock is a condition in which your heart suddenly can't pump enough blood to meet your body's needs. The condition is most often caused by a severe heart attack. Cardiogenic shock is rare, but it's often fatal if not treated immediately. If treated immediately, about half the people who develop the condition survive.

  • Cardiogenic shock

    Treatment: During this treatment, which most people who have cardiogenic shock need, you're given extra oxygen to breathe, to minimize damage to your muscles and organs. If necessary, you'll be connected to a breathing machine (ventilator). You'll receive medications and fluid through an intravenous (IV) line in your arm. Medications to treat cardiogenic shock work to improve blood flow through your heart and increase your heart's pumping ability such as Aspirin, Thrombolytics, Superaspirins, Other blood-thinning medications, Inotropic agents. Medical procedures to treat cardiogenic shock usually focus on restoring blood flow through your heart. They include: Angioplasty and stenting, Balloon pump. If medications and medical procedures don't work to treat cardiogenic shock, your doctor may recommend surgeries are Coronary artery bypass surgery, Surgery to repair an injury to your heart, Heart pumps, Heart transplant.

  • Cardiogenic shock

    Research: The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective according to results of a European study of patients with acute ST-elevation myocardial infarction (STEMI). Results for TRO40303 are a surprising contrast to promising earlier studies that had generated high hopes for the agent. "Negative studies rarely lead to phenomenal breakthroughs and monumental change-of-practice, but it is important to be aware that negative studies increase our understanding of disease and of therapeutic options," he said. The study's finding of lack of benefit of TRO40303, "provides important information on current state-of-the-art STEMI treatment, and may reflect the fact that the high quality of modern care leaves little room for improvement." TRO40303 has been shown in animals and laboratory models to block mitochondrial permeability that leads to reperfusion injury. When blocked vessels that cause a heart attack (infarct) are cleared, allowing reperfusion, cardiac muscle may be injured causing what is known as an infarct expansion. Mitochondrial permeability has been shown to play an important role in this process

  • Cardiogenic shock

    Statistics: The incidence rate of cardiogenic shock ranges from 5-10% in patients with acute myocardial infarction (MI). In the Worcester Heart Attack Study, a community-wide analysis, the reported incidence rate was 7.5%.[4] The literature contains few data on cardiogenic shock in patients without ischemia. Cardiogenic shock occurs in 8.6% of patients with ST-segment elevation MI (STEMI), with 29% of those presenting to the hospital already in shock. It occurs only in 2% of patients with non ̶ ST-segment elevation acute coronary syndrome (NSTACS). Several multicenter thrombolytic trials in Europe reported a prevalence rate of cardiogenic shock following MI of approximately 7%. Race-stratified mortality rates from cardiogenic shock are as follows (race-based mortality differences disappear with revascularization): • Hispanics - 74% • African Americans - 65% • Whites - 56% • Asians/others - 41% The overall incidence of cardiogenic shock is higher in men than in women, with females accounting for 42% of patients with cardiogenic shock. This difference results from the increased prevalence of coronary artery disease in males. However, a higher percentage of female patients with MI develop cardiogenic shock than do males with MI. Median age for cardiogenic shock mirrors the bimodal distribution of disease. For adults, the median age ranges from 65-66 years. For children, cardiogenic shock presents as a consequence of fulminant myocarditis or congenital heart disease.

Expert PPTs
  • Adrian M Baranchuk
    Brugada Phenocopy: Update 2014
    PPT Version | PDF Version
  • Jun Qin
    Innovation of Acoustic Research on Biomedical Applications
    PPT Version | PDF Version
  • Yue Zhang
    Genetics and Epigenetics, Systems biology, SLAC ( Stem cell biology, longevity /Ageing and cancer biology) with a focus on chromatin remodelers w/o the stressors, particularly radiation, heat shock, and nutrient deprivation by using both C.elegans model organisms and mammalian systems.
Speaker PPTs

High Impact List of Articles

Conference Proceedings